ES2067457T3 - Celula de origen animal con una proteina antigenica introducida en ella. - Google Patents

Celula de origen animal con una proteina antigenica introducida en ella.

Info

Publication number
ES2067457T3
ES2067457T3 ES88109455T ES88109455T ES2067457T3 ES 2067457 T3 ES2067457 T3 ES 2067457T3 ES 88109455 T ES88109455 T ES 88109455T ES 88109455 T ES88109455 T ES 88109455T ES 2067457 T3 ES2067457 T3 ES 2067457T3
Authority
ES
Spain
Prior art keywords
separately
cells
animal origin
antigenic protein
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88109455T
Other languages
English (en)
Inventor
Yves C Nicolau
Garret M Ihler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hapgood CV
Original Assignee
Hapgood CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26748809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2067457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hapgood CV filed Critical Hapgood CV
Application granted granted Critical
Publication of ES2067457T3 publication Critical patent/ES2067457T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555—Red blood cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)

Abstract

ESTA INVENCION COMPRENDE CELULAS ANIMALES DERIVADAS, EN ESPECIAL ERITROCITOS QUE HAN SIDO MODIFICADAS ARTIFICIALMENTE PARA QUE INCORPOREN EN SUS MEMBRANAS PLASMATICAS UN ANTIGENO, LA PROTEINA CD4 DERIVADA DE LINFOCITOS, LOQUE HACE QUE DE SEPAREN SELECTIVAMENTE Y SE CONDENSEN CON OTRAS CELULAS INFESTADAS CON UN VIRUS, ESPECIALMENTE VIRUS DE SIDA. ESTAS CELULAS MODIFICADAS PUEDEN SER ALTERADAS POSTERIORMENTE PATA QUE CONTENGAN EN SU CITOPLASMA UN AGENTE CITOTOXICO EN CUAL DESPUES DE QUE LA CELULA SE FUNDE CON UNA CELULA DIANA DARA LUGAR A LA MUERTE DE AMBAS CELULAS, CON LA SUBSIGUIENTE SEPARACION DEL SISTEMA RETICULOENDOTELIAL. TAMBIEN SE INCLUYE LA PRODUCCION Y EMPLEO DE LIPOSOMAS MODIFICADOS SIMILARMENTE. LA INVENCION PUEDE USARSE PARA EL TRATATAMIENTO DEL SIDA Y OTRAS ENFERMEDADES VIRICAS.
ES88109455T 1987-06-30 1988-06-14 Celula de origen animal con una proteina antigenica introducida en ella. Expired - Lifetime ES2067457T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6828887A 1987-06-30 1987-06-30
US19744588A 1988-05-27 1988-05-27

Publications (1)

Publication Number Publication Date
ES2067457T3 true ES2067457T3 (es) 1995-04-01

Family

ID=26748809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88109455T Expired - Lifetime ES2067457T3 (es) 1987-06-30 1988-06-14 Celula de origen animal con una proteina antigenica introducida en ella.

Country Status (9)

Country Link
US (1) US5677176A (es)
EP (1) EP0298280B1 (es)
JP (2) JP2728166B2 (es)
AT (1) ATE114476T1 (es)
AU (2) AU1821988A (es)
CA (1) CA1327332C (es)
DE (1) DE3852221T2 (es)
ES (1) ES2067457T3 (es)
IL (1) IL86650A0 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
CA1327174C (en) * 1988-10-05 1994-02-22 Youssef Mouneimne Electro-insertion of proteins into animal cell membranes
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes
US5235023A (en) * 1988-12-22 1993-08-10 The Dow Chemical Company Process for synthesis of heterocyclic polymers with trihalomethyl azole-forming site
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
EP0555333B1 (en) * 1990-10-19 1995-12-27 University Of Florida Artificial viral envelopes
US5753258A (en) * 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
EP0517986B1 (en) * 1991-06-14 1997-09-10 Communaute Economique Europeenne (Cee) Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions
EP0630407B1 (en) * 1992-03-11 2000-08-02 PRENDERGAST, Kenneth, Francis Anti-viral fusion peptides
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
WO1994004677A1 (en) * 1992-08-13 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of cd4 plasma membrane vesicles (pmv) as a therapeutic agent for aids
AU671158B2 (en) * 1992-09-22 1996-08-15 Dnx Biotherapeutics, Inc. Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
ATE177431T1 (de) * 1994-07-15 1999-03-15 Biosearch Italia Spa Dinukleosid-5',5'- pyrophosphate
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
WO2000029556A2 (en) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of glycosphingolipids that promote hiv-1 entry into cells
BR9816113A (pt) 1998-12-23 2001-10-23 Idea Ag Formulação aperfeiçoada para aplicação tópica não-invasiva in vivo
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
EP1921451A3 (en) * 2001-05-22 2008-05-28 Cygene, Inc. Complement mediated assays for in vivo and in vitro methods
EA006577B1 (ru) * 2001-10-16 2006-02-24 Киуи Индженьюити Лимитид Контроли чувствительности для серологии крови, приготовленные из модифицированных клеток
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CA2719567A1 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20110070153A1 (en) * 2008-08-13 2011-03-24 Searete, Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
JP5822836B2 (ja) * 2009-10-08 2015-11-24 大塚製薬株式会社 悪性腫瘍の治療のための免疫活性化血液灌流フィルタ
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
PL3125927T3 (pl) 2014-04-01 2021-07-19 Rubius Therapeutics, Inc. Sposoby i kompozycje do immunomodulacji

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
FR2564319A1 (fr) * 1984-05-21 1985-11-22 Inst Nat Sante Rech Med Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes

Also Published As

Publication number Publication date
US5677176A (en) 1997-10-14
DE3852221D1 (de) 1995-01-12
EP0298280A2 (en) 1989-01-11
DE3852221T2 (de) 1995-04-06
IL86650A0 (en) 1988-11-30
JP2728166B2 (ja) 1998-03-18
ATE114476T1 (de) 1994-12-15
EP0298280B1 (en) 1994-11-30
AU1942692A (en) 1992-09-24
CA1327332C (en) 1994-03-01
AU1821988A (en) 1989-04-27
EP0298280A3 (en) 1990-05-02
JPH1072368A (ja) 1998-03-17
AU662154B2 (en) 1995-08-24
JPH01124382A (ja) 1989-05-17
JP2825804B2 (ja) 1998-11-18

Similar Documents

Publication Publication Date Title
ES2067457T3 (es) Celula de origen animal con una proteina antigenica introducida en ella.
DK319481A (da) Fremgangsmaade til fremstilling af forbindelse indeholdende 2-phenyl-1,2-benzioselenazol-3(2h)-on
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ES2170771T3 (es) Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
ATE27915T1 (de) Kovalente konjugate,die ein enzym und einen antikoerper verbinden und medikamentoese zubereitungen,die diese konjugate enthalten.
ES2109254T3 (es) Proteinas antigenas y vacunas que las contienen para la prevencion de cocidiosis.
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
FI882912A (fi) Laekemedelspreparat med finfoerdelade ebselen-kristaller.
ES2033667T3 (es) Composicion farmaceutica que contiene fracciones de extractos de timo.
ES2118058T3 (es) Factor de crecimiento de las celulas t.
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
ATE95564T1 (de) Aeusseres membranprotein f von pseudomonas aeruginosa.
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
DE69528170D1 (de) Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
FI881122A (fi) Menetelmä tyvikalvoproteiinien eristämiseksi ihmis- ja eläinkudoksista
DE60027581D1 (de) Design von immunogene
NO179855C (no) Fremgangsmåte for fremstilling av et legemiddel
ES2059826T3 (es) Utilizacion de quimotripsina para inactivar el activador de precalicreina en productos sanguineos derivados de plasma humano o animal.
Hamilton et al. The role of calcium binding protein in the mechanism of action of cholecalciferol (vitamin D3)
ES2061731T3 (es) Procedimiento de extraccion de antigenos de membrana con propiedades inmunogenicas de celulas neoplasicas humanas y los productos asi obtenidos.
Murray Secretory Antibody and Local Immunity: Secretory Antibody and Local Immunity: Effector Mechanisms of Immediate Hypersensitivity at Mucosal Surfaces
McCulloch Saint Euphrosine, Saint Alexis, and the Turtledove
Fujimaki et al. Mast Cell Response to Formaldehyde: 2. Induction of Stress-Like Proteins

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 298280

Country of ref document: ES